NCT04518124View on ClinicalTrials.gov

Propranolol in Angiosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Angiosarcoma
Interventions
DRUG

Propranolol

Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.

Trial Locations (1)

Unknown

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
collaborator

Anticancer Fund, Belgium

OTHER

lead

The Netherlands Cancer Institute

OTHER

NCT04518124 - Propranolol in Angiosarcoma | Biotech Hunter | Biotech Hunter